The use of autologous stem cell transplantation (ASCT) for the treatment of multiple myeloma is increasing. Anticoagulation may be required during ASCT for conditions such as Hickman line thrombosis. The safety of anticoagulation in patients receiving ASCT is unknown. We report a retrospective case-control study of the safety of therapeutic anticoagulation in patients with multiple myeloma receiving ASCT. We identified 10 patients who received therapeutic anticoagulation during ASCT. For each of the 10 cases identified, two matched controls were selected. As a primary endpoint, bleeding complications were assessed. Secondary endpoints included survival, length of hospital stay, transfusion requirements, grade 4 toxicity, and days to platelet engraftment. Bleeding complications were not significantly different between patients receiving anticoagulation and controls (P = 0.3). Three of 10 anticoagulated patients and two of 20 controls had a bleeding complication. Mortality during admission was similar (P = 1.0); one anticoagulated patient and one control died of sepsis. A trend towards increased median number of platelet transfusions in the heparinized patients was seen (27 vs 12 units, P = 0.055), reflecting the higher transfusion threshold chosen for the anticoagulated patients. The other secondary endpoints did not differ between patients and controls. In this case control study, bleeding was not significantly increased in the group receiving anticoagulation during ASCT. This group electively received more units of platelets than controls. Thus, therapeutic anticoagulation can be managed with minimal increased toxicity during ASCT.
Autologous stem cell transplantation (ASCT) has been shown in a randomized trial to prolong survival in patients with multiple myeloma 1 with the result that ASCT in multiple myeloma is increasing. Hickman line catheters are required for ASCT and these lines carry a 10-37% risk of thrombosis. 2 conditions such as Hickman line thrombosis, has the potential to increase the risk of minor and major hemorrhage. In a study by Landefeld et al, 3 1011 general medical patients starting anticoagulation were reviewed for evidence of bleeding. Major bleeding occurred in 6% and minor bleeding occurred in 9% of the cohort. Prognostic variables for an increased bleeding risk included age greater than 60 years, liver dysfunction, comorbid illnesses, and a prothrombin time (PT) or a partial thromboplastin time (PTT) greater than two times control.
To our knowledge, the use of therapeutic anticoagulation during ASCT has not been reported previously. Low dose intravenous heparin (100 units/kg/day) has been used during allotransplant to prevent veno-occlusive disease of the liver without any increased risk of bleeding. 4, 5 The use of thrombolytic therapy after allotransplant for the treatment of pulmonary embolism has been described in three cases. 6 All three patients died and two had major hemorrhagic complications. Complications from therapeutic anticoagulation therapy might be higher in patients receiving ASCT than in general medical patients due to the concomitant thrombocytopenia, anemia and mucositis accompanying high-dose therapy. We report a retrospective case-control study on the incidence of bleeding and complications among a group of patients receiving anticoagulation during ASCT for multiple myeloma.
Materials and methods

Patients
Records of 93 consecutive patients with myeloma undergoing ASCT between 1992 and 1997 at the University of Toronto Autologous Blood and Marrow Transplant Program were reviewed. We identified 10 patients who received therapeutic anticoagulation therapy during ASCT. Anticoagulation was required following pre-transplant subclavian vein thrombosis complicating Hickman catheters (n = 8) which occurred a median of 2 months prior to ASCT (median 3 days to 35 months), pulmonary embolus 2 months prior to transplant (n = 1), or a 5-year history of acute intermittent atrial fibrillation complicated by an arterial embolus to the leg (n = 1). Starting on the first day of high-dose chemotherapy, the 10 patients received therapeutic unfractionated heparin (5000 U intravenous bolus followed by 1000 U per h) to maintain a PTT 50-70 s and were switched to coumadin when their conditions stabil-ized. The heparin was stopped once the coumadin produced a therapeutic INR у 2 for 2 consecutive days. For each of the 10 cases identified, two controls who received ASCT for multiple myeloma were randomly selected from a list of all patients with myeloma who had received an ASCT at our center. The individual selecting the controls was aware of the patient's age, myeloablative regimen and gender, but was blinded to the patient's outcome during and after transplant. The controls were matched for the following characteristics in priority: age at transplant ±5 years, myeloablative regimen and gender.
Treatments
Following ASCT, heparinized patients received platelet transfusions to maintain a count у30 × 10 9 /l; controls received platelets to maintain a count у10 × 10 9 /l, or у20 × 10 9 /l if they were febrile. Patients and controls were transfused to maintain a hemoglobin concentration у80 g/l. Controls received 1 mg of coumadin per day. This dose of coumadin has been shown to reduce the incidence of Hickman line thrombosis, but does not prolong the INR. 2 
Endpoints
Records of patients and controls were reviewed and primary and secondary endpoints were assessed. As a primary endpoint, bleeding complications were assessed and graded according to the modified WHO classification: WHO class 1, minor bleeding including mucocutaneous hemorrhage and epistaxis; WHO class 2, melena, hematemesis, gross hematuria and hemoptysis; WHO class 3, bleeding requiring transfusion; WHO class 4, intracranial hemorrhage or fresh retinal hemorrhage with impairment of vision. 7 Secondary endpoints included survival, length of hospital stay, transfusion requirements, grade 4 toxicity, time to platelet engraftment, and the median platelet count from the time of ASCT to discharge.
Statistical analysis
Differences in bleeding, survival, and toxicity were determined by 2 and Fisher's exact analyses. The differences in median length of hospital stay, transfusion requirements, and platelet counts were determined by the Mann-Whitney U test. A Student t-test determined differences between patients and controls for mean PT and PTT values. Table 1 summarizes the characteristics of the 10 patients and 20 controls included in the study. The median age of the 10 patients at the time of transplant was 52 years (range 40-58). The median age of the 20 controls was 50.5 years (range 36-60). Among the patients, there were seven men and three women. There were 12 men and eight women among the controls. These differences are not significant. The patients received three different high intensity chemotherapy regimens prior to transplant: (1) etoposide 60 mg/kg, melphalan 160 mg/m 2 , and 1200 cGY total body irradiation (n = 5); (2) busulfan 14 mg/kg and cyclophosphamide 120 mg/kg (n = 3); or (3) melphalan 140 mg/m 2 and 1200 cGY total body irradiation (n = 2).
Results
The 10 anticoagulated patients received a median of 18 days (range 5-43) of intravenous unfractionated heparin therapy.
Bleeding complications
Three of 10 anticoagulated patients and two of 20 controls had a bleeding complication. Among the anticoagulated patients, the three initial bleeding episodes were WHO class 2 (hematemesis or gross hematuria). All three initial bleeding complications in the anticoagulated patients occurred during heparin therapy. One patient developed hematuria 4 days after ASCT. This patient was receiving anticoagulation for a Hickman line thrombosis which occurred 2 months prior to ASCT. The heparin was discontinued at the time of bleeding and anticoagulation was not restarted. A second patient developed hematemesis 8 days after ASCT. This patient was receiving anticoagulation for a pulmonary embolus which occurred 2 months prior to ASCT. In response to the bleed, the heparin was held for 7 days and then restarted at the same dose. He had no further bleeding episodes and was discharged home on coumadin. The third patient was receiving anticoagulation for an extensive Hickman line thrombosis 35 months prior to ASCT. She experienced a small volume hematemesis 4 days after ASCT, mucosal bleeding 23 days after ASCT and melena 33 and 38 days after ASCT. The patient was receiving heparin at the time of the hematemesis and mucosal bleeding. In response to these bleeding episodes the heparin was held for 1 day. She was receiving coumadin when she developed melena on day 33, and no anticoagulation at the time of the melena on day 38. At the time of the first episode of melena on day 33, she had an INR of 3.12 and a platelet count of 14 × 10 9 /l. In response to this bleeding episode, five units of platelets were transfused and the coumadin was stopped for 15 days. Coumadin was then restarted and no further bleeding ensued. She was discharged home on coumadin. No other blood products or protamine sulphate were administered to any of the other patients as treatment for the bleeding complications.
The two bleeding complications in the controls were WHO class 2 (hematochezia or gross hematuria). One patient developed hematuria 4 days after ASCT, and required no therapy. The other patient developed hematochezia 24 days after ASCT. This patient received a platelet transfusion in response to the bleeding, because his platelet count was 8 × 10 9 /l. On the day of the initial bleeding complication in the anticoagulated patients, the median PTT was 75 s (range, 66.7-83.1), the median PT was 12.6 s (range, 12.2-32.3), and the median platelet count was 35 × 10 9 /l (range 33-50 × 10 9 /l). In the two control patients who bled, the PTTs at the time of bleeding were 39.3 and 40.2 s. The platelet counts were 70 × 10 9 /l and 8 × 10 9 /l and the PTs were 11.4 and 18.2 s. The mean PTT for the anticoagulated patients during ASCT was 70.9 ± 15 s and the mean PT was 15.6 ± 4 s. In the patients who bled, the mean PTT (P = 0.7) and PT (P = 0.5) during the ASCT were not significantly *P = 0.86; **P = 0.72; ***P = 0.159.
higher than the anticoagulated patients who did not bleed. At the time of the bleeding episode, no patients or controls had liver or renal dysfunction.
Secondary endpoints
Mortality during admission was similar (P = 1.0) between patients and controls. One anticoagulated patient and one control died from sepsis. Table 2 summarizes the other secondary endpoints. A trend to increased platelet transfusions was seen in the anticoagulated group. The anticoagulated group received a median of 27 units of platelets and the control group received a median of 12 units of platelets (P = 0.055). The median platelet count from the time of ASCT to discharge did not differ between the patients and controls (65 × 10 9 /l and 68 × 10 9 /l respectively, P = 0.47). The incidence of grade 4 toxicity was similar between anticoagulated patients and controls. One anticoagulated patient experienced grade 4 toxicity (death from sepsis) compared to three controls (death from sepsis, seizure secondary to busulfan, and acute tubular necrosis). Median units of red cells transfused, median length of hospital stay, and median days to platelet engraftment did not differ significantly between the patients and the controls.
Discussion
In our study, 30% of anticoagulated patients and 10% of controls had bleeding complications during ASCT. None of the bleeding complications was major (WHO class 3 or 4) or required transfusion. To our knowledge, no prior study has examined the safety of therapeutic doses of 7 reported a case series of five patients treated with low molecular weight heparin for Hickman catheter-induced thrombosis during autologous bone marrow transplant. The thromboses occurred a median of 22 days (range, 10-34) after transplant. The patients were treated with low molecular weight heparin for 14 days after diagnosis of the thrombus. The low molecular weight heparin was well tolerated in this group. None of the five patients had a bleeding complication.
Our incidence of bleeding is higher than the risk of bleeding reported in patients not receiving anticoagulation after bone marrow transplant. 8 In an autopsy series of 83 patients who had previously received an allotransplant or autotransplant for acute leukemia, six (7%) patients had bleeding complications between the time of transplant and engraftment. In three of these six cases, bleeding complications were fatal, and occurred between 6 and 24 days after transplant. The majority of bleeding episodes after transplant occurred in the time after engraftment (20/83) or at relapse of disease (12/83). The study did not comment on the use of ASA.
Our estimate of bleeding risk among anticoagulated patients is higher than the risk of bleeding among general medical patients receiving anticoagulation. Landefeld et al 3 reported a risk of major bleeding of 6% and minor bleeding of 9% in his cohort. He identified prognostic variables that increased the risk of bleeding. Due to our small sample size, we cannot comment on prognostic variables in our group.
A trend towards increased platelet transfusion in the heparinized patients was seen reflecting the higher transfusion threshold. No other differences were observed among the secondary endpoints including overall survival, length of hospital stay, toxicity and days to platelet engraftment.
We limited our study to patients with myeloma because we were aware of all patients with multiple myeloma who required anticoagulation during ASCT at our center. In addition, ASCT is not a curative procedure for multiple myeloma, 1 so the toxicity from ASCT is a significant factor when deciding whether to proceed with this treatment option.
We conclude that therapeutic anticoagulation produces minimal increased toxicity and no increased mortality or significant morbidity during ASCT. This group electively received more units of platelets than the controls. Requirement for anticoagulation is not a contraindication to stem cell transplant, although larger studies are required before anticoagulation during ASCT can be viewed as safe. On balance, the benefits of ASCT appear to outweigh the potential risks of anticoagulation during periods of prolonged thrombocytopenia.
